Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Sickle Cell Disease Treatment Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Sickle Cell Disease Treatment Industry
  • 1.7 COVID-19 Impact: Sickle Cell Disease Treatment Market Trends

    • 2 Global Sickle Cell Disease Treatment Quarterly Market Size Analysis

    • 2.1 Sickle Cell Disease Treatment Business Impact Assessment - COVID-19
      • 2.1.1 Global Sickle Cell Disease Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Sickle Cell Disease Treatment Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Sickle Cell Disease Treatment Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Sickle Cell Disease Treatment Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Sickle Cell Disease Treatment Market
    • 3.4 Key Players Sickle Cell Disease Treatment Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Sickle Cell Disease Treatment Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Sickle Cell Anemia
      • 1.4.2 Sickle Beta Thalassemia
      • 1.4.3 Sickle Hemoglobin C Disease
    • 4.2 By Type, Global Sickle Cell Disease Treatment Market Size, 2019-2021

    5 Impact of Covid-19 on Sickle Cell Disease Treatment Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hospitals
      • 5.5.2 Clinics
      • 5.5.3 Others
    • 5.2 By Application, Global Sickle Cell Disease Treatment Market Size, 2019-2021
      • 5.2.1 By Application, Global Sickle Cell Disease Treatment Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 AstraZeneca
      • 7.1.1 AstraZeneca Business Overview
      • 7.1.2 AstraZeneca Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.1.3 AstraZeneca Sickle Cell Disease Treatment Product Introduction
      • 7.1.4 AstraZeneca Response to COVID-19 and Related Developments
    • 7.2 Eli Lilly
      • 7.2.1 Eli Lilly Business Overview
      • 7.2.2 Eli Lilly Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.2.3 Eli Lilly Sickle Cell Disease Treatment Product Introduction
      • 7.2.4 Eli Lilly Response to COVID-19 and Related Developments
    • 7.3 Novartis
      • 7.3.1 Novartis Business Overview
      • 7.3.2 Novartis Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.3.3 Novartis Sickle Cell Disease Treatment Product Introduction
      • 7.3.4 Novartis Response to COVID-19 and Related Developments
    • 7.4 Pfizer
      • 7.4.1 Pfizer Business Overview
      • 7.4.2 Pfizer Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.4.3 Pfizer Sickle Cell Disease Treatment Product Introduction
      • 7.4.4 Pfizer Response to COVID-19 and Related Developments
    • 7.5 Baxter
      • 7.5.1 Baxter Business Overview
      • 7.5.2 Baxter Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.5.3 Baxter Sickle Cell Disease Treatment Product Introduction
      • 7.5.4 Baxter Response to COVID-19 and Related Developments
    • 7.6 Emmaus Life Sciences
      • 7.6.1 Emmaus Life Sciences Business Overview
      • 7.6.2 Emmaus Life Sciences Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.6.3 Emmaus Life Sciences Sickle Cell Disease Treatment Product Introduction
      • 7.6.4 Emmaus Life Sciences Response to COVID-19 and Related Developments
    • 7.7 Bluebird bio
      • 7.7.1 Bluebird bio Business Overview
      • 7.7.2 Bluebird bio Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.7.3 Bluebird bio Sickle Cell Disease Treatment Product Introduction
      • 7.7.4 Bluebird bio Response to COVID-19 and Related Developments
    • 7.8 Blood Therapeutics
      • 7.8.1 Blood Therapeutics Business Overview
      • 7.8.2 Blood Therapeutics Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.8.3 Blood Therapeutics Sickle Cell Disease Treatment Product Introduction
      • 7.8.4 Blood Therapeutics Response to COVID-19 and Related Developments
    • 7.9 Sangamo Therapeutics
      • 7.9.1 Sangamo Therapeutics Business Overview
      • 7.9.2 Sangamo Therapeutics Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.9.3 Sangamo Therapeutics Sickle Cell Disease Treatment Product Introduction
      • 7.9.4 Sangamo Therapeutics Response to COVID-19 and Related Developments
    • 7.10 Acceleron Pharma
      • 7.10.1 Acceleron Pharma Business Overview
      • 7.10.2 Acceleron Pharma Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.10.3 Acceleron Pharma Sickle Cell Disease Treatment Product Introduction
      • 7.10.4 Acceleron Pharma Response to COVID-19 and Related Developments
    • 7.11 Arena Pharmaceuticals
      • 7.11.1 Arena Pharmaceuticals Business Overview
      • 7.11.2 Arena Pharmaceuticals Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.11.3 Arena Pharmaceuticals Sickle Cell Disease Treatment Product Introduction
      • 7.11.4 Arena Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.12 Alnylam Pharmaceuticals
      • 7.12.1 Alnylam Pharmaceuticals Business Overview
      • 7.12.2 Alnylam Pharmaceuticals Sickle Cell Disease Treatment Quarterly Revenue, 2020
      • 7.12.3 Alnylam Pharmaceuticals Sickle Cell Disease Treatment Product Introduction
      • 7.12.4 Alnylam Pharmaceuticals Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Sickle Cell Disease Treatment, including the following market information:
      Global Sickle Cell Disease Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Sickle Cell Disease Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Sickle Cell Disease Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Sickle Cell Disease Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include AstraZeneca, Eli Lilly, Novartis, Pfizer, Baxter, Emmaus Life Sciences, Bluebird bio, Blood Therapeutics, Sangamo Therapeutics, Acceleron Pharma, Arena Pharmaceuticals, Alnylam Pharmaceuticals, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Sickle Cell Anemia
      Sickle Beta Thalassemia
      Sickle Hemoglobin C Disease

      Based on the Application:
      Hospitals
      Clinics
      Others

      Buy now